期刊文献+

含乌司他丁造影剂胰管显影与ERCP术后胰腺炎相关性研究 被引量:2

Clinical randomizing control trial for the imaging of pancreatic duct and post ERCP pancreatitis:a method using a contrast medium with Ulinastatin
暂未订购
导出
摘要 目的用含乌司他丁造影剂显影胰管,以观察ERCP术后胰腺炎的发生率和预防的临床对照研究。方法将2008年1月至2009年7月上海交通大学医学院附属仁济医院嘉定分院178例患者随机分成对照组85例、实验组93例,实验组用含乌司他丁造影剂显影胰管、而对照组用常规造影剂,操作要求用缓力推注造影剂且仅显示主胰管。结果178例发生ERCP术后胰腺炎共15例,发生率为8.9%,其中对照组11例、占12.9%(11/85),实验组4例、占4.3%(4/93),两组发生率比较差异有统计学意义P<0.05,诊断性ERCP术后胰腺炎发生率,对照组和实验组分别为44.4%(4/9)和14.3%(1/7),统计分析差异无统计学意义P>0.05。全部患者为轻型胰腺炎,经保守治疗痊愈。结论在ERCP术操作中使用含乌司他丁造影剂显影胰管,能降低ERCP术后胰腺炎的发生率,但不能完全避免术后胰腺炎的发生。 Objective The aim of this trail for the observation and prevention to incidence rate of Post ERCP Pancreatitis (PEP) by using the contrast medium with contained Uinastatin to developing of pancreatic duct after ERCP procedure. Methods 178 patients were selected to perform ERCP procedure from 2008. 1 to 2009. 1 ,that were divided into two groups, in which 93 cases in study group were been imaged the pancreatic duct by using contrast media with contained Ulinastatin, and 85 patients in control group by developing of pancreatic duct with conventional medium. The degree of developing pancreatic duct was controlled to limit master pancreatic duct by softly injection pressure,not to exposure its branches. Results 15 of 178 cases occurred to the post ERCP pancreatitis, total incidence rate of 8. 9%, which of 11 cases were in control group, and 4 patients in study group. The incidence rate of PEP was 12. 9% in control group and 4. 3 % in study group, that were significant differences to compare the results between both groups ( P 〈 0. 05 ). The incidence rate of PEP after diagnostic ERCP was 44.4% 4/9 ) and 14. 3% (1/7) in control group and study group, respectively, the statistical analysis demonstrated no significant differences between both groups (P 〉 0. 05 ). The symptom of PEP presented slightly in 15 patients, they were cured by conservative therapy. Conclusion The incidence rate of PEP can be reduced by using contained Ulinastatin contrast medium to developing of pancreatic duct after ERCP procedure, but not yet to avoid the occurrence of post ERCP pancreatitis entirely.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2010年第3期256-256,257,260,共3页 Chinese Journal of Practical Internal Medicine
关键词 逆行胰胆造影术 ERCP术后胰腺炎 造影剂 乌司他丁 ERCP post ERCP pancreatitis contrast medium Ulinastatin
  • 相关文献

参考文献9

  • 1Johnson GK, Geenen Je, Bedford RA, et al. A comparison of nonionic versus ionic contrast media: result of a prospective, multi- center study[ J]. Gastrointest Endose, 1995,42:312 - 316.
  • 2Johnson GK, C, eenen JE, Johnson JF, et al Evaluation of post-ER- CP panereatitis: potential causes noted during eontroUes study of differing contrast media. Midwest Pancreaticohiliary Study Group [ J]. Gastrointest Endosc, 1997,46:217 - 222.
  • 3Cheng CL,Sherman S,Watkins JL,et al. Risk factors for post-ERCP panereatitis:a prospective multicenter study[ J ]. Am J Gastroenterol,2006,101 ( 1 ) :139 - 147.
  • 4许晓倩,张文俊,李兆申.ERCP术后胰腺炎[J].胰腺病学,2003,3(4):243-247. 被引量:20
  • 5闫波,赵建妹,沈云志,孙克文,秦怡.ERCP术后胰腺炎的影响因素分析[J].胰腺病学,2007,7(3):178-180. 被引量:10
  • 6李兆申,张文俊,潘雪,龚彪,智发朝,郭学刚,李培明,范志宁,孙文生,沈云志,麻树人,谢渭芬,陈旻湖,李延青.奥曲肽预防ERCP术后胰腺炎及高淀粉酶血症的多中心随机对照临床研究[J].中华消化内镜杂志,2004,21(5):301-305. 被引量:60
  • 7Minoru O, Naoki W, Mashiro M, et al. New endoscopic treatment for chronic pancreatitis, using contrast media containing ulinastatin and prednisolone[ J]. J Gastroenter, 1997,32:216 - 221.
  • 8曾文红,白国强.乌司他丁研究进展[J].中华肝胆外科杂志,2001,7(1):52-54. 被引量:143
  • 9李兆申,许国铭,孙振兴,邹晓平,金震东,邹多武.诊断性与治疗性ERCP早期并发症与处理[J].中华消化内镜杂志,2002,19(2):77-80. 被引量:205

二级参考文献66

  • 1Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc ,2001,54:425-434.
  • 2Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis:a randomized controlled trial. Gastrointest Endosc, 1999,49: 593 -598.
  • 3Cotton PB, Lehman G, Yennes J, et al. Endoscopic sphincterotomy complications and their management:an attempt at consensus. Gastrointest Endosc, 1991,37:383-393.
  • 4Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc, 1998,48:1-10.
  • 5Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am J Gastroenterol,2001,96 :417-423.
  • 6Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc ,2002,55:470-475.
  • 7Freeman ML. Precut (access) sphincterotomy. Techniques in Gastrointest Endoscopy, 1999,1:40-48.
  • 8Cotton PB. Precut papillotomy: a risky technique for experts only.Gastrointest Endosc, 1989,35:578-579.
  • 9Vandervoort J, Carr-Locke DL. Needle-knife access papillotomy: an unfairly maliged technique? Endoscopy, 1996,28:365-366.
  • 10Huibregtse K, Katon RM,Tytgat GN. Precut papillotomy via needleknife papillotome: a safe and effective technique. Gastrointest Endosc, 1986,32:403-405.

共引文献424

同被引文献39

  • 1胡骁骅,张会英,葛艳玲,陈忠,覃凤均,蒋海燕,陈大福,孙永华.乌司他丁对严重烧伤后多脏器功能的保护作用[J].中华医学杂志,2005,85(41):2889-2894. 被引量:55
  • 2FRANK C D, ADLER D G. Post - ERCP pancreatitis and its pre- vention[ J]. Nat Clin Pract Gastroenterol Hepatol, 2006, 3 (12) : 680 - 688.
  • 3POON R T, YEUNG C, LO C M, et al. Prophylactic effect ofso- matostatin on post - ERCP pancreatitis: a randomized controlled trim [ J ]. Gastrointest Endosc, 1999, 49 (5) : 593 - 598.
  • 4GRANT S, AITCHISON T, HENDERSON E, et al. A comparison of the reproducibility and the sentitivity to change of visual ana- logue scales, Borg scales, and during submaximal exercise[ J ]. 1217. Liken scales in normal subjects Chest, 1999, 116(5): 1208-.
  • 5DONNELLAN F, BYRNE M F. Prevention of Post - ERCP Pan- creatitis [ J ]. Gastroenterol Res Pract, 2012, 2012 : 796751.
  • 6MASCI E, MARIANI A, CURIONI S, et al. Risk factors for pan- creatitis following endoscopic retrograde cholangiopancreatography: a meta - analysis[ J]. Endoscopy, 2003, 35 (10) : 830 - 834.
  • 7CHENG C L, SHERMAN S, WATKINS J L, et al. Risk factors for post - ERCP pancreatitis : a prospective muhicenter study [ J ]. Am J Gastroenterol, 2006, 101 ( 1 ) : 139 - 147.
  • 8FREEMAN M L, DISARIO J A, NELSON D B, et al. Risk fac- tors for post - ERCP pancreatitis : a prospective, multicenter study [ J ]. Gastrointest Endosc, 2001, 54 (4) : 425 - 434.
  • 9高峻,李兆申.胰腺疾病内镜诊断与治疗学[M].上海:第二军医大学出版社,2004:337-340.
  • 10CHOI C W, KANG D H, KIM G H, et al. Nafamostat mesylate in the prevention of post - ERCP pancreatitis and risk factors for post - ERCP pancreatitis [ J ]. Gastrointest Endosc, 2009, 69 (4) : el 1 - elS.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部